Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

The 2 faces of ERK2 in MPNs.

Havelange V. and Constantinescu SN., (2022), Blood, 140, 298 - 300

Studying severe long COVID to understand post-infectious disorders beyond COVID-19.

Brodin P. et al, (2022), Nature medicine, 28, 879 - 882

JAK inhibitors and COVID-19.

Levy G. et al, (2022), Journal for immunotherapy of cancer, 10

Human genetic and immunological determinants of critical COVID-19 pneumonia

Zhang Q. et al, (2022), Nature

Degrading JAK2 in ALL by ruxolitinib-based PROTACs

Constantinescu SN. and Pecquet C., (2021), Blood, 138, 2301 - 2302

MPL S505C enhances driver mutations at W515 in essential thrombocythemia.

Varghese LN. et al, (2021), Blood cancer journal, 11

Pituitary incidentaloma.

Constantinescu SM. and Maiter D., (2021), Presse medicale (Paris, France : 1983)

Inferring the dynamic of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms.

Mosca M. et al, (2021), Blood

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.

Bastard P. et al, (2021), Science immunology, 6

CALR mutant protein rescues the response of MPL p.R464G variant associated with CAMT to eltrombopag.

Basso-Valentina F. et al, (2021), Blood

Functional Consequences of Mutations in Myeloproliferative Neoplasms

Constantinescu SN. et al, (2021), HemaSphere

Include forthcoming?